BioCryst Pharmaceuticals, Inc.

BCRX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009
Operating Activities
Net Income $-13.5M
Depreciation & Amortization —
Depreciation —
Amortization —
Stock-Based Compensation $5.5M
Net Cash from Operating Activities $-16.2M
Investing Activities
Capital Expenditures $604.0K
Business Acquisitions —
Net Cash from Investing Activities $-12.9M
Financing Activities
Dividends Paid —
Stock Repurchases $155.0K
Net Cash from Financing Activities $47.9M
Net Change in Cash $18.8M
Free Cash Flow $-16.8M
← Newer Page 3 of 3 Older →